LongBio Pharma (Suzhou) (SEHK:1779) Stock Looks Rich With A 65.1x P B Multiple

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Key recent moves in LongBio Pharma (Suzhou) stock

LongBio Pharma (Suzhou) (SEHK:1779) has drawn investor attention after a recent 2% daily gain and a modest 0.6% rise over the past week. This has prompted closer scrutiny of this early-stage biopharmaceutical stock.

The company focuses on discovering and developing treatments for allergic and autoimmune diseases in China and Hong Kong. It currently reports no revenue and a loss of CN¥175.583 million, which frames how investors may assess risk and potential.

See our latest analysis for LongBio Pharma (Suzhou).

With the share price at HK$142.8 and a year to date share price return of 8.35%, the recent 1 day and 7 day gains suggest short term momentum is building for LongBio Pharma (Suzhou) as investors reassess its risk and early stage pipeline.

If this kind of early stage biotech story interests you, it can be useful to compare it with other healthcare companies using AI by checking out 133 healthcare AI stocks

With LongBio Pharma (Suzhou) still loss making and trading at HK$142.8, investors are left weighing its early pipeline against current expectations. Is this pricing conservative, or is the market already baking in future growth?

Preferred price-to-book multiple of 65.1x for LongBio Pharma (Suzhou) stock: is it justified?

On a simple yardstick, LongBio Pharma (Suzhou) looks expensive at HK$142.8, as its current P/B of 65.1x sits far above both the Hong Kong biotechs industry and peer averages.

The P/B ratio compares the market value of a company to its net assets. This can be a useful cross check for early stage businesses that do not yet generate revenue or profits. For LongBio Pharma (Suzhou), investors are paying a large multiple of the company’s book value despite CN¥0 in revenue and a reported loss of CN¥175.583 million, which points to expectations that sit well ahead of the current financial base.

Compared with the Hong Kong biotechs industry average P/B of 3.2x and a peer average of 4.5x, LongBio Pharma (Suzhou)’s 65.1x multiple is very high in relative terms. This large gap suggests the market is assigning a substantial premium to its pipeline and future potential versus both the sector and close peers.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-book of 65.1x (OVERVALUED)

However, LongBio Pharma (Suzhou) is still loss making with CN¥175.583 million reported, and any pipeline setback or funding pressure could quickly challenge today’s valuation story.

Find out about the key risks to this LongBio Pharma (Suzhou) narrative.

Next Steps

Given the mixed signals around LongBio Pharma (Suzhou)’s valuation and risks, it makes sense to review the details promptly and form your own stance. A practical place to begin is the 2 important warning signs.

Looking for more investment ideas beyond LongBio Pharma (Suzhou)?

If LongBio Pharma (Suzhou) has caught your attention, it is worth broadening your watchlist so you are not relying on a single early stage biotech story.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include 1779.HK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com